Edwards Lifesciences (NYSE:EW) Rating Increased to Hold at Sanford C. Bernstein

Sanford C. Bernstein upgraded shares of Edwards Lifesciences (NYSE:EW) from a strong sell rating to a hold rating in a research note released on Monday, Zacks.com reports.

Other equities research analysts also recently issued reports about the company. Barclays cut their price target on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th. Evercore ISI dropped their target price on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. Truist Financial decreased their price target on Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating for the company in a report on Friday, October 25th. Oppenheimer reaffirmed an “outperform” rating and set a $90.00 price objective on shares of Edwards Lifesciences in a research note on Thursday, September 12th. Finally, StockNews.com lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Thursday, July 25th. Sixteen analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $75.67.

Edwards Lifesciences Trading Down 1.1 %

Shares of NYSE:EW opened at $68.63 on Monday. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08. Edwards Lifesciences has a 52-week low of $58.93 and a 52-week high of $96.12. The stock has a market cap of $41.36 billion, a price-to-earnings ratio of 29.58, a PEG ratio of 3.00 and a beta of 1.13. The business has a 50-day moving average price of $68.07 and a 200-day moving average price of $77.92.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.67. The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. Edwards Lifesciences’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period last year, the firm posted $0.59 EPS. Equities analysts predict that Edwards Lifesciences will post 2.61 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In other news, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the sale, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, VP Daveen Chopra sold 1,250 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the transaction, the vice president now directly owns 29,333 shares in the company, valued at $2,051,843.35. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total value of $333,850.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,133,916.72. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 16,250 shares of company stock valued at $1,099,238 over the last ninety days. Insiders own 1.29% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Price T Rowe Associates Inc. MD increased its stake in Edwards Lifesciences by 57.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock worth $622,695,000 after acquiring an additional 2,390,137 shares during the last quarter. CCLA Investment Management increased its position in shares of Edwards Lifesciences by 100,739.7% during the 1st quarter. CCLA Investment Management now owns 1,406,714 shares of the medical research company’s stock worth $134,092,000 after purchasing an additional 1,405,319 shares during the last quarter. Swedbank AB purchased a new stake in Edwards Lifesciences in the 1st quarter valued at about $124,511,000. Sei Investments Co. lifted its position in Edwards Lifesciences by 162.7% in the first quarter. Sei Investments Co. now owns 1,465,719 shares of the medical research company’s stock valued at $140,064,000 after buying an additional 907,688 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Edwards Lifesciences by 4.3% during the second quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock worth $1,827,347,000 after buying an additional 809,605 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.